MGI Pharma is developing irofulven, a semi-synthetic compound derived from illudin S, a toxin from the Omphalotus illudens mushroom, for the potential treatment of refractory and relapsed tumors, including ovarian, prostate, hepatocellular, breast, lung and colon cancers. Phase II trials of the compound as a monotherapy or in combination therapies are ongoing for a number of these indications.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
mgi pharma
8
irofulven mgi
4
pharma mgi
4
pharma developing
4
developing irofulven
4
irofulven semi-synthetic
4
semi-synthetic compound
4
compound derived
4
derived illudin
4
illudin toxin
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!